Goodrx (GDRX) Stock
Consumer technology platform for prescription drug price comparison. Here's the price, business snapshot, and what's worth knowing about Goodrx in September 2026.
GoodRx Holdings, Inc. (GDRX) runs a consumer-focused platform that helps people compare prescription drug prices, access discount coupons and use telehealth services. The company generates revenue from advertising, transaction fees, and subscription services like GoodRx Gold. With a market capitalisation of about $1.35 billion, GoodRx sits at the intersection of healthcare and consumer technology, offering a potentially scalable model but one that remains sensitive to regulatory changes, pharmacy reimbursement structures and competition. Investors should know that revenue can be cyclical and tied to drug pricing dynamics and healthcare policy. GoodRx’s user base and partnerships are important growth levers, while margins and cash flow depend on how the company balances marketing, innovation and emerging services. This is general educational information and not personalised advice; stock prices can fall as well as rise, so suitability depends on an investor’s goals, timeframe and risk tolerance.
Goodrx (GDRX) Stock Forecast
Analyst price target, next 12 months
$6.57
+96.2% vs today's $3.35
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Goodrx have a consensus 12-month target of $6.57, above the current price of $3.35.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 28 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding GoodRx's stock with a target price of $6.57, indicating possible growth.
Financial Health
GoodRx is performing well with strong revenue and profits, though cash flow is lower than expected.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Usage and reach
GoodRx’s monthly active users and partnerships drive traffic and monetisation opportunities, though user growth can be cyclical and competitive.
Revenue mix matters
Income from advertising, transactions and subscriptions provides diversification, but changes in pharmacy pricing or regulation could affect margins.
Policy and competition
Regulatory decisions and rival digital-health offerings can reshape the outlook; investors should weigh potential upside against execution and regulatory risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
